Literature DB >> 23729376

Interleukin-22 serum levels are a negative prognostic indicator in patients with hepatocellular carcinoma.

Oliver Waidmann1, Bernd Kronenberger, Patrick Scheiermann, Verena Köberle, Heiko Mühl, Albrecht Piiper.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23729376     DOI： 10.1002/hep.26528

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  19 in total

Review 1.  Biological and pathological activities of interleukin-22.

Authors:  Mirna Perusina Lanfranca; Yanwei Lin; Jingyuan Fang; Weiping Zou; Timothy Frankel
Journal:  J Mol Med (Berl)       Date:  2016-02-29       Impact factor: 4.599

Review 2.  Interleukin-22: immunobiology and pathology.

Authors:  Jarrod A Dudakov; Alan M Hanash; Marcel R M van den Brink
Journal:  Annu Rev Immunol       Date:  2015-02-11       Impact factor: 28.527

3.  Th22/IL-22 mediates the progression of HBV-related hepatocellular carcinoma via STAT3.

Authors:  Jia Zhang; Zhou Liu; Lingpeng Liu; Mingwen Huang; Yong Huang
Journal:  Cytotechnology       Date:  2022-02-22       Impact factor: 2.058

4.  Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice.

Authors:  Tim Hendrikx; Yi Duan; Yanhan Wang; Jee-Hwan Oh; Laura M Alexander; Wendy Huang; Peter Stärkel; Samuel B Ho; Bei Gao; Oliver Fiehn; Patrick Emond; Harry Sokol; Jan-Peter van Pijkeren; Bernd Schnabl
Journal:  Gut       Date:  2018-11-17       Impact factor: 23.059

5.  Biologically active, high levels of interleukin-22 inhibit hepatic gluconeogenesis but do not affect obesity and its metabolic consequences.

Authors:  Ogyi Park; Sung Hwan Ki; Mingjiang Xu; Hua Wang; Dechun Feng; Joseph Tam; Douglas Osei-Hyiaman; George Kunos; Bin Gao
Journal:  Cell Biosci       Date:  2015-05-30       Impact factor: 7.133

6.  The Role of IL-22 in Viral Infections: Paradigms and Paradoxes.

Authors:  Silvia Gimeno Brias; Gabrielle Stack; Maria A Stacey; Alec J Redwood; Ian R Humphreys
Journal:  Front Immunol       Date:  2016-05-30       Impact factor: 7.561

7.  Tristetraprolin regulation of interleukin-22 production.

Authors:  Lorena Härdle; Malte Bachmann; Franziska Bollmann; Andrea Pautz; Tobias Schmid; Wolfgang Eberhardt; Hartmut Kleinert; Josef Pfeilschifter; Heiko Mühl
Journal:  Sci Rep       Date:  2015-10-21       Impact factor: 4.379

Review 8.  Immunopathobiology and therapeutic targets related to cytokines in liver diseases.

Authors:  Yong He; Seonghwan Hwang; Yeni Ait Ahmed; Dechun Feng; Na Li; Marcelle Ribeiro; Fouad Lafdil; Tatiana Kisseleva; Gyongyi Szabo; Bin Gao
Journal:  Cell Mol Immunol       Date:  2020-11-17       Impact factor: 11.530

Review 9.  STAT3, a Key Parameter of Cytokine-Driven Tissue Protection during Sterile Inflammation - the Case of Experimental Acetaminophen (Paracetamol)-Induced Liver Damage.

Authors:  Heiko Mühl
Journal:  Front Immunol       Date:  2016-05-02       Impact factor: 7.561

10.  Though Active on RINm5F Insulinoma Cells and Cultured Pancreatic Islets, Recombinant IL-22 Fails to Modulate Cytotoxicity and Disease in a Protocol of Streptozotocin-Induced Experimental Diabetes.

Authors:  Anika Berner; Malte Bachmann; Christine Bender; Josef Pfeilschifter; Urs Christen; Heiko Mühl
Journal:  Front Pharmacol       Date:  2016-01-12       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.